The US Latent TB Testing Market was valued at $163.12 Million in 2024 and projected to reach to $189.58 Million by 2029, representing a compound annual growth rate of 3.1%. The US latent TB testing market is positioned for steady growth through 2029, supported by increasing awareness of tuberculosis screening importance in clinical practice and occupational health settings.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US latent TB testing market reached $163.12 million in 2024, with projected growth to $189.58 million by 2029, representing a steady 3.1% CAGR driven by enhanced screening protocols.
Interferon-gamma release assays (IGRAs) are experiencing increased adoption across US healthcare facilities due to superior specificity compared to tuberculin skin tests and reduced cross-reactivity with BCG vaccination.
Strengthened CDC-led TB elimination programs and targeted screening in high-risk populations including healthcare workers, immigrants, and immunocompromised individuals are accelerating market expansion across US regions.
Growing integration of latent TB testing into routine occupational health screenings and pre-employment medical evaluations in US hospitals and clinics is driving consistent market demand.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | HOUSEHOLD CONTACTS WITH PULMONARY TB (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | IGRA (Test Type) |
| Market Size Base Year (Billions) | ~USD 0.58 (2024) |
| Revenue Forecast (Billions) | ~USD 0.77 (2029) |
| Segments Covered | Test Type, Application, End User |
3 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 10.33 | 11.63 | 11.61 | 11.66 | 11.82 | 12.05 | 12.36 | 12.71 | 1.8 |
| DIAGNOSTIC LABORATORIES | 113.6 | 129.63 | 131.04 | 133.39 | 136.99 | 141.49 | 146.96 | 153.1 | 3.2 |
| HOSPITALS & CLINICS | 33.55 | 37.98 | 38.09 | 38.46 | 39.18 | 40.15 | 41.37 | 42.76 | 2.3 |
| OTHER END USERS | 5.37 | 6.02 | 5.98 | 5.97 | 6.03 | 6.11 | 6.24 | 6.38 | 1.3 |
| TOTAL | 162.86 | 185.26 | 186.71 | 189.49 | 194.02 | 199.8 | 206.91 | 214.94 | 2.9 |
The US latent TB testing market was valued at $163.12 million in 2024 and is expected to reach $189.58 million by 2029.
The US latent TB testing market is growing at a compound annual growth rate (CAGR) of 3.1% from 2024 to 2029.
Key drivers include occupational health screening requirements, immigration medical examinations, healthcare worker protocols, and increased adoption of interferon-gamma release assays (IGRAs).
Interferon-gamma release assays (IGRAs) are the preferred testing modality in the US, offering advantages over tuberculin skin tests in terms of specificity and ease of administration.
Expected innovations include point-of-care testing solutions, digital health integration, rapid testing methodologies, and expanded reimbursement coverage to improve accessibility and diagnostic efficiency.
The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | General Manager |
| Revvity | Area Sales Manager |
Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.
Full forecast, segment splits, and company analysis for all Latent TB Testing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report